Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biogaia Adr Class B BIOGY

Healthcare Biotechnology
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics... see more

Recent & Breaking News (PINL:BIOGY)

FoundationOne® Identifies Clinically Relevant Genomic Alterations in Patients with Advanced Breast Cancers

Business Wire December 9, 2014

Teva Canada Announces the Launch of (Pr)Teva-Erlotinib, a generic of (Pr)Tarceva®

Canada NewsWire December 9, 2014

GlycoMimetics Highlights Potential Therapeutic Benefits of Its Novel E-Selectin Antagonist at 56th ASH Annual Meeting

Business Wire December 9, 2014

Acetylon Pharmaceuticals Announces Ricolinostat Continues to Demonstrate Clinically Meaningful and Durable Disease Response Rates in Phase 1b Combination Studies in Multiple Myeloma

Business Wire December 9, 2014

US Oncology Research Announces Schedule of Presentations at the 2014 CTRC-AACR San Antonio Breast Cancer Symposium

Business Wire December 9, 2014

Eurofins Expands Microbiology Division in California

PR Newswire December 9, 2014

TI expands IoT cloud ecosystem and simplifies code development with open-source Energia support

PR Newswire December 9, 2014

Seattle Children's Reprogrammed T Cell Immunotherapy Clinical Trial Boasts 85% Complete Remission Rate in Children with Relapsed Leukemia

PR Newswire December 9, 2014

App Annie Now Offering Free Windows Store Support

PR Newswire December 9, 2014

Genomic Health Advances Development of Novel Liquid Biopsy-Based Cancer Tests

PR Newswire December 9, 2014

Global Agricultural Biotechnology Market to Reach $46.8 Billion in 2019; Biotech Tools Surging at 49.9% CAGR

PR Newswire December 9, 2014

Applied DNA Sciences Elects Joseph Ceccoli to Board of Directors

Marketwired December 9, 2014

BeyondSpring Pharmaceuticals Names Dr. Yan Sun as Principal Investigator for Global Phase 3 Lung Cancer Clinical Trial of Plinabulin

GlobeNewswire December 9, 2014

Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update

Business Wire December 9, 2014

Paul Allen donates $100 million for research on the human cell

UPI December 9, 2014

Sanford I. Weill Retires as Chair of the Weill Cornell Board of Overseers After 20 Years of Transformative Leadership

PR Newswire December 9, 2014

Sobi CEO Geoffrey McDonough sells a portion of 2014 incentive shares

Thomson Reuters ONE December 9, 2014

Scaled Agile Framework ® (SAFe) Bolsters Persistent Systems' Partner Ecosystem for Digital Transformation

PR Newswire December 9, 2014

Solving Organ Shortage Convenes Top Scientists to Explore Ways to Regenerate or Bioengineer Human Lungs

Business Wire December 9, 2014

New Management of Biostem Technologies (BSEM) Announces Name and Symbol Change to Be in Effect Today; BSEM Also Moves Forward to Complete an Interactive Webpage and Will Be Attending the 22nd Annual World Congress on Anti-Aging Medicine Dec 11-13, 2014

Marketwired December 9, 2014